Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884285 · ClinicalTrials.gov registry record · Phase 1
AZD8186 First Time In Patient Ascending Dose Study
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
NCT01884285: Completed Phase 1 study, sponsored by AstraZeneca.
NCT01884285 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 147 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (145% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01884285, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanced solid malignancies as monotherapy and in combination with abiraterone acetate or AZD2014.
Primary Outcome
Assess safety and tolerability of AZD8186 when given as monotherapy or in combination with abiraterone acetate (with prednisone) or with AZD2014 by measuring AEs, SAE (incl death), safety measures incl ECG, physical exam, pulse, blood pressure, weight, lab variables
Interventions
- DRUG Part A: AZD8186 monotherapy
- DRUG Part B: AZD8186 monotherapy
- DRUG Part C1: Abiraterone acetate combination with AZD8186
- DRUG Part D1: AZD2014 combination with AZD8186
- DRUG Part D2 AZD2014 combination with AZD8186
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2013-07-09 |
| Est. Completion | 2020-02-07 |
| Phase | Phase 1 |
What the finished NCT01884285 record still lists
NCT01884285 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (145% higher).
The record links to 0 conditions, and to 5 interventions - of which Part A: AZD8186 monotherapy is the first listed.
NCT01884285 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01884285 about?
NCT01884285 is a clinical study titled "AZD8186 First Time In Patient Ascending Dose Study". This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB mutated/amplified advanc...
What is the current status of trial NCT01884285?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2013-07-09. Estimated completion is 2020-02-07.
What interventions are being tested in trial NCT01884285?
The interventions under investigation include: Part A: AZD8186 monotherapy (DRUG), Part B: AZD8186 monotherapy (DRUG), Part C1: Abiraterone acetate combination with AZD8186 (DRUG), Part D1: AZD2014 combination with AZD8186 (DRUG), Part D2 AZD2014 combination with AZD8186 (DRUG).
Who is sponsoring clinical trial NCT01884285?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01884285's enrollment target sits among peer trials
147 387th of 2000 higher than 1,610 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI